Full Press Release Details
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation
on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis
Pliant has initiated assembly of outside panel of world-renowned experts
to review BEACON-IPF trial data
SOUTH SAN FRANCISCO, CA., February 13, 2025 - Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that, per the charter of the trial s
independent Data Safety Monitoring Board (DSMB), the Company has initiated the assembly of an outside expert panel to review unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients
with idiopathic pulmonary fibrosis (IPF). The panel, consisting of world-renowned experts in pulmonary diseases and biostatistics, will provide an independent recommendation to Pliant regarding the BEACON-IPF
trial. Subsequently, the panel will serve as part of an expanded DSMB with the goal to reach a consensus recommendation regarding BEACON-IPF. The decision to assemble the outside panel was taken as the Company
has not been able, through review of blinded data, to determine the rationale for the DSMB s recommendation to pause enrollment and dosing in the trial. The Company expects this process to conclude in two to four weeks.
Following the DSMB s previously announced recommendation, Pliant voluntarily paused enrollment and dosing in the
BEACON-IPF clinical trial. Pliant is committed to remaining blinded ensuring the data integrity of the BEACON-IPF 2b clinical trial with the goal of maintaining its
potential to serve as a registrational trial.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic
diseases. Pliant s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of v 6 and
v 1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or IPF.
Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and Orphan Drug Designation from the European Medicines Agency in IPF. Pliant has initiated
BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule,
dual-selective inhibitor of v 8 and v 1 integrins, that is being developed for the treatment of
solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin 7 1 targeting muscular dystrophies.
Forward-Looking Statements
Statements contained in this
press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect,
anticipate, estimate, intend, and similar
expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those
regarding the Company s, the DSMB s and the outside expert panel s further review and analysis of data, the ability of the outside expert panel and the DSMB to reach a consensus recommendation regarding
BEACON-IPF and the timing thereof, and the Company s current and future plans for bexotegrast and the BEACON-IPF clinical trial. Because such statements deal with
future events and are based on our current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Pliant Therapeutics could differ materially from those described in or implied by the
statements in this press release. These forward-looking statements are subject to risks and uncertainties, including those related to the development and commercialization of our product candidates, including any delays in our ongoing or planned
preclinical or clinical trials, the risks inherent in the drug development process, the risks regarding the accuracy of our estimates of expenses and timing of development, and our capital requirements and the need for additional financing,
including the availability of additional term loans under our loan facility. These and additional risks are discussed in the sections titled Risk Factors and Management s Discussion and Analysis of Financial Condition and
Results of Operations in our Quarterly Report on Form 10-Q for the period ended September 30, 2024, which is available on the SEC s website at www.sec.gov. Unless otherwise noted,
Pliant is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Investor and Media Contact:
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.